|  | 100% positive assessments 1 | 0–49% positive assessments 2 | ||||||
---|---|---|---|---|---|---|---|---|---|
 |  | Prev.(%) | PR | Adj. PR | 95% CI | Prev.(%) | PR | Adj. PR | 95% CI |
Gender | |||||||||
(N = 25154) | Female | 64.5 | 1 | 13 | Â | 19.7 | 1 | 1 | Â |
 | Male | 64.4 | 1.00 | 0.95 | 0.93 – 0.97 | 19.1 | 0.97 | 1.05 | 0.99 – 1.11 |
Age (years) | |||||||||
(N = 25154) | 18–24 | 52.4 | 1 | 13 |  | 25.0 | 1 | 1 |  |
 | 25–29 | 55.5 | 1.06 | 1.04 | 0.97 – 1.12 | 23.7 | 1.03 | 0.96 | 0.84 – 1.10 |
 | 30–34 | 57.8 | 1.10 | 1.10 | 1.03 – 1.18 | 22.9 | 1.00 | 0.90 | 0.79 – 1.02 |
 | 35–39 | 60.2 | 1.15 | 1.18 | 1.11 – 1.26 | 22.5 | 1.01 | 0.84 | 0.74 – 0.94 |
 | 40–44 | 61.0 | 1.16 | 1.23 | 1.15 – 1.32 | 22.6 | 1.00 | 0.79 | 0.70 – 0.90 |
 | 45–49 | 62.1 | 1.19 | 1.28 | 1.19 – 1.37 | 21.1 | 0.90 | 0.71 | 0.61 – 0.81 |
 | 50–54 | 63.9 | 1.22 | 1.34 | 1.26 – 1.43 | 18.8 | 0.88 | 0.61 | 0.53 – 0.70 |
 | 55–59 | 68.8 | 1.31 | 1.47 | 1.37 – 1.57 | 17.2 | 0.74 | 0.54 | 0.47 – 0.63 |
 | 60–64 | 70.9 | 1.35 | 1.52 | 1.42 – 1.62 | 16.2 | 0.67 | 0.51 | 0.44 – 0.59 |
 | 65–69 | 75.1 | 1.43 | 1.61 | 1.50 – 1.72 | 13.1 | 0.58 | 0.41 | 0.35 – 0.49 |
 | 70–74 | 75.6 | 1.44 | 1.62 | 1.52 – 1.73 | 14.4 | 0.53 | 0.46 | 0.39 – 0.54 |
 | 75–79 | 71.7 | 1.37 | 1.56 | 1.45 – 1.67 | 15.1 | 0.51 | 0.47 | 0.40 – 0.56 |
 | 80+ | 73.7 | 1.41 | 1.61 | 1.50 – 1.72 | 14.2 | 0.57 | 0.43 | 0.36 – 0.51 |
Further education (years) | |||||||||
(N = 24003) | None | 65.9 | 1 | 13 | Â | 19.1 | 1 | 1 | Â |
 | Less than 2 | 65.1 | 0.95 | 1.02 | 0.98 – 1.06 | 20.6 | 1.08 | 1.03 | 0.92 – 1.15 |
 | 2–4 | 64.1 | 0.85 | 0.99 | 0.96 – 1.01 | 19.5 | 1.02 | 1.01 | 0.93 – 1.08 |
 | 5 or more | 63.5 | 0.73 | 0.97 | 0.94 – 1.01 | 19.4 | 1.01 | 1.01 | 0.92 – 1.11 |
 | Undergoing education or other | 63.9 | 0.84 | 1.02 | 0.97 – 1.07 | 18.7 | 0.97 | 0.91 | 0.79 – 1.06 |
Frequency of attendance (times per year) | |||||||||
(N = 25154) | 0–1 | 63.9 | 1 | 13 |  | 22.5 | 1 | 1 |  |
 | 2–3 | 63.1 | 0.99 | 1.01 | 0.98 – 1.05 | 20.8 | 0.93 | 0.89 | 0.81 – 0.98 |
 | 4–5 | 63.8 | 1.00 | 1.03 | 1.00 – 1.07 | 18.9 | 0.84 | 0.79 | 0.71 – 0.86 |
 | 6–7 | 65.7 | 1.03 | 1.09 | 1.05 – 1.13 | 19.4 | 0.86 | 0.75 | 0.68 – 0.83 |
 | 8–9 | 66.0 | 1.03 | 1.11 | 1.06 – 1.16 | 18.5 | 0.82 | 0.70 | 0.62 – 0.79 |
 | 10+ | 66.6 | 1.04 | 1.17 | 1.12 – 1.22 | 16.5 | 0.73 | 0.57 | 0.51 – 0.63 |
Duration of listing (years) | |||||||||
(N = 16745) | Less than 1 | 63.9 | 1 | 13 | Â | 20.2 | 1 | 1 | Â |
 | 1–2 | 65.4 | 1.02 | 0.99 | 0.94 – 1.05 | 18.8 | 0.93 | 1.01 | 0.88 – 1.17 |
 | 3–7 | 65.0 | 1.02 | 0.97 | 0.92 – 1.01 | 18.5 | 0.91 | 1.02 | 0.90 – 1.16 |
 | 8–12 | 66.0 | 1.03 | 0.96 | 0.91 – 1.01 | 18.2 | 0.90 | 1.05 | 0.91 – 1.21 |
 | 13+ | 68.2 | 1.07 | 0.98 | 0.93 – 1.03 | 17.0 | 0.84 | 1.01 | 0.88 – 1.16 |
Self-rated health | |||||||||
(N = 25154) | Excellent | 71.2 | 1 | 13 | Â | 15.7 | 1 | 1 | Â |
 | Very good | 66.9 | 0.94 | 0.89 | 0.87 – 0.92 | 17.2 | 1.10 | 1.21 | 1.09 – 1.35 |
 | Good | 64.5 | 0.91 | 0.77 | 0.75 – 0.80 | 19.7 | 1.26 | 1.72 | 1.55 – 1.91 |
 | Fair | 58.8 | 0.83 | 0.66 | 0.63 – 0.68 | 23.4 | 1.50 | 2.38 | 2.12 – 2.68 |
 | Poor | 55.8 | 0.78 | 0.62 | 0.58 – 0.66 | 26.5 | 1.69 | 2.82 | 2.42 – 3.29 |
Chronic condition | |||||||||
(N = 24795) | No | 63.7 | 1 | 13 | Â | 20.2 | 1 | 1 | Â |
 | Yes-KRTC | 70.9 | 1.11 | 1.07 | 1.05 – 1.10 | 15.5 | 0.77 | 0.82 | 0.75 – 0.89 |
 | Yes-other or multiple | 62.1 | 0.98 | 1.02 | 0.99 – 1.04 | 20.6 | 1.02 | 0.90 | 0.85 – 0.97 |
Chronic condition | |||||||||
(N = 16860) | None | 63.7 | 1 | 13 | Â | 20.2 | 1 | 1 | Â |
 | K – Cardiovascular | 73.0 | 1.15 | 1.09 | 1.05 – 1.13 | 14.3 | 0.71 | 0.80 | 0.71 – 0.91 |
 | R – Respiratory | 65.5 | 1.03 | 1.06 | 1.01 – 1.11 | 19.5 | 0.97 | 0.91 | 0.79 – 1.04 |
 | T – Endocrine | 70.7 | 1.11 | 1.08 | 1.03 – 1.13 | 15.0 | 0.74 | 0.79 | 0.68 – 0.92 |
 | C – Cancer | 76.8 | 1.21 | 1.21 | 1.13 – 1.31 | 11.1 | 0.55 | 0.53 | 0.37 – 0.75 |